These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30238583)

  • 1. Atopic-like dermatitis after secukinumab injection: A case report.
    Burlando M; Cozzani E; Russo R; Parodi A
    Dermatol Ther; 2019 Jan; 32(1):e12751. PubMed ID: 30238583
    [No Abstract]   [Full Text] [Related]  

  • 2. Remittive effect of Dupilumab in atopic dermatitis.
    Treister AD; Lio PA
    Dermatol Ther; 2018 Nov; 31(6):e12711. PubMed ID: 30253014
    [No Abstract]   [Full Text] [Related]  

  • 3. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 4. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab.
    Vestergaard C; Deleuran M; Kragballe K
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1272-4. PubMed ID: 17894730
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti IL-17 flared psoriasis in a patient on secukinumab.
    Noell C; McQuade B; Gottlieb A; Rosmarin D
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
    [No Abstract]   [Full Text] [Related]  

  • 6. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients.
    Samorano LP; Hanifin JM; Simpson EL; Leshem YA
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):522-3. PubMed ID: 25510643
    [No Abstract]   [Full Text] [Related]  

  • 7. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
    Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioral dermatitis.
    Lancet; 1980 Jan; 1(8159):75-6. PubMed ID: 6101421
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
    Bissonnette R; Luger T; Thaçi D; Toth D; Messina I; You R; Guana A; Fox T; Papavassilis C; Gilloteau I; Mrowietz U
    Br J Dermatol; 2017 Oct; 177(4):1033-1042. PubMed ID: 28580579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 13. Tremfya™ (Guselkumab).
    Abramovits W; Wiqas A; Vincent KD; Versteeg SG; Gupta AK
    Skinmed; 2019; 17(1):36-38. PubMed ID: 30888946
    [No Abstract]   [Full Text] [Related]  

  • 14. Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect?
    Loi C; Patrizi A; Sechi A; Tartari F; Magnano M; Bardazzi F
    G Ital Dermatol Venereol; 2018 Aug; 153(4):590-591. PubMed ID: 29767491
    [No Abstract]   [Full Text] [Related]  

  • 15. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy.
    Chan JL; Davis-Reed L; Kimball AB
    J Drugs Dermatol; 2004; 3(3):315-8. PubMed ID: 15176169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis.
    Egeberg A; Thyssen JP
    J Am Acad Dermatol; 2019 Oct; 81(4):943-949. PubMed ID: 31202869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrodermic psoriasis and secukinumab: Our clinical experience.
    Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
    Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
    Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
    J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
    [No Abstract]   [Full Text] [Related]  

  • 19. ARTICLE: Colloidal Oatmeal Part II: Atopic Dermatitis in Special Populations and Clinical Efficacy and Tolerance Beyond Eczema.
    Allais B; Friedman A
    J Drugs Dermatol; 2020 Oct; 19(10):s8-s11. PubMed ID: 33026769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.